Acelyrin Adopts Poison Pill
Acelyrin Adopts Poison Pill as Tang Capital Partners Builds Stake
The late-stage biopharma said the plan will issue one right for each share of common stock as of the close of business on March 24. The rights will initially trade with its common stock, and will become exercisable only if any person acquires 10% or more of Acelyrin's outstanding common stock.
Acelyrin and Pliant Therapeutics, both of which are viewed as takeover targets for Kevin Tang’s Concentra Biosciences, each adopted a “poison pill” on Thursday morning.
Acelyrin (NASDAQ:SLRN) shares lost ~32% after the clinical-stage biotech announced new results from a Phase 2 trial for lonigutamab, an injectable targeted at thyroid eye disease (TED) and ...
Acelyrin has declined a surprise offer from Concentra Biosciences, and is instead pushing ahead with plans to merge with immune-mediated disease specialist Alumis. Los Angeles-based Acelyrin ...
Concentra Biosciences offers $3/share + CVR for Acelyrin, outperforming Alumis' bid. Read why I rate SLRN stock a Sell at ...
The drama introduces a potential choice for Acelyrin shareholders: cash now in a deal with Concentra or a potentially bigger return from the all-stock merger with Alumis. Two weeks after Alumis ...
Alumis (ALMS) and ACELYRIN (SLRN) reaffirmed their commitment to merge in an all-stock transaction, which will create a leading clinical stage biopharma company in immune-mediated diseases.
In this article, we are going to take a look at where Acelyrin, Inc. (NASDAQ:SLRN) stands against the other micro cap stocks. Just as we overlook loose change, micro-cap stocks are often ignored ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback